SPRY profile · all as-reported value updates

ARS Pharmaceuticals, Inc. (SPRY) as-reported value updates

Descriptive filing record — not investment advice. This page compares two SEC XBRL-filed values for the same fiscal period. It does not state why the values differ and is not a rating, score, or recommendation. See Disclaimer.

Reported values for the same fiscal period can differ between filings for many routine reasons: re-presentation for discontinued operations, adoption of new accounting standards, reclassifications, changes in rounding precision, and amendments. This ledger records that the filed values differ; it does not and cannot determine why. Both filings are linked below so the reader can consult the source.

Rows publish only when the later filed value differs by at least 1.0% and at least $1,000,000, after dropping differences that match under the capped trailing-zero precision rule. The delta percent is delta divided by the larger absolute filed value. Values are annual standardized facts only; metrics whose differences fall below those thresholds or match the capped precision rule are not published as rows.

Ledger table figure

Metric	FY	Earliest XBRL-filed value	Currently on file	Difference	Difference %	Label	Filing links	Notes
Stockholders' equity StockholdersEquity	2021	313,815,000 filed 2022-03-31 · 10-K	-31,269,000 filed 2024-03-21 · 10-K	-345,084,000	-109.96%	revised comparative figure	0000950170-22-005202 0000950170-24-034689	3 filed observations examined for this concept and period.
Stockholders' equity StockholdersEquity	2020	382,877,000 filed 2022-03-31 · 10-K	-14,052,000 filed 2023-03-23 · 10-K	-396,929,000	-103.67%	revised comparative figure	0000950170-22-005202 0000950170-23-009491	2 filed observations examined for this concept and period. Earliest observation is a comparative value in a later annual filing.
Capital expenditures PaymentsToAcquirePropertyPlantAndEquipment	2021	1,372,000 filed 2022-03-31 · 10-K	55,000 filed 2023-03-23 · 10-K	-1,317,000	-95.99%	revised comparative figure	0000950170-22-005202 0000950170-23-009491	2 filed observations examined for this concept and period.
Assets Assets	2021	333,467,000 filed 2022-03-31 · 10-K	61,446,000 filed 2023-03-23 · 10-K	-272,021,000	-81.57%	revised comparative figure	0000950170-22-005202 0000950170-23-009491	2 filed observations examined for this concept and period.
Operating income OperatingIncomeLoss	2021	-89,584,000 filed 2022-03-31 · 10-K	-19,454,000 filed 2023-03-23 · 10-K	70,130,000	+78.28%	revised comparative figure	0000950170-22-005202 0000950170-23-009491	2 filed observations examined for this concept and period.
Net income NetIncomeLoss	2021	-89,478,000 filed 2022-03-31 · 10-K	-20,243,000 filed 2023-03-23 · 10-K	69,235,000	+77.38%	revised comparative figure	0000950170-22-005202 0000950170-23-009491	2 filed observations examined for this concept and period.
Cash and cash equivalents CashAndCashEquivalentsAtCarryingValue	2021	254,045,000 filed 2022-03-31 · 10-K	60,063,000 filed 2023-03-23 · 10-K	-193,982,000	-76.36%	revised comparative figure	0000950170-22-005202 0000950170-23-009491	2 filed observations examined for this concept and period.
Operating cash flow NetCashProvidedByUsedInOperatingActivities	2021	-66,760,000 filed 2022-03-31 · 10-K	-17,561,000 filed 2023-03-23 · 10-K	49,199,000	+73.70%	revised comparative figure	0000950170-22-005202 0000950170-23-009491	2 filed observations examined for this concept and period.
Liabilities Liabilities	2021	19,652,000 filed 2022-03-31 · 10-K	16,676,000 filed 2023-03-23 · 10-K	-2,976,000	-15.14%	revised comparative figure	0000950170-22-005202 0000950170-23-009491	2 filed observations examined for this concept and period.